Sunitinib is safe and as effective as neoadjuvant and adjuvant treatment for patients with metastatic renal cell carcinoma (mRCC) undergoing nephrectomy, according to a small study from the United Kingdom.
Sarah Welsh, MD, a researcher at Cambridge University in Cambridge, U.K., and her colleagues enrolled 14 patients with mRCC who were undergoing nephrectomy to receive 50 mg of sunitinib (Sutent, Pfizer) daily for 12 days preoperatively, then postoperatively for four weeks, followed by a